Understanding the molecular mechanisms by which DDX24 and DDX49 inhibit reactivation could lead to therapeutic strategies for EBV and KSHV malignancies whose pathogenesis is driven by both the latent and lytic phases of infection. This evidence concerns the gene DDX24 and infection.